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Rationale: A subgroup of patients with chronic obstructive pulmonary disease require frequent
hospitalization because of exacerbations of the disease. We hypothesized that airway infection
by non-usual pathogens is a major factor driving hospitalization needs in these patients.
Objectives: 1) To describe the clinical and functional characteristics of a cohort of COPD
patients requiring 2 hospitalizations per year; 2) to determine prospectively their microbio-
logical pattern during exacerbations; and, 3) to analyze the prognostic value of several clin-
ical, functional and microbiological variables with respect to hospitalizations and mortality.
Methods: Open cohort study of 116 COPD patients who had been hospitalized at least twice
during the last 12 months. Patients were followed for an average of 21 months.
Measurements and main results: Clinical data, forced spirometry and 6 min walking distance
were determined, and the BODE index was calculated, at the time of inclusion in the study.
During follow-up, sputum culture was obtained during exacerbations, and hospitalization
and mortality were collected every two months. Mean age was 71 yrs, and 94% of patients were
male. Main findings show that: 1) not all patients had severe disease according to either the
degree of airflow limitation or the BODE index; 2) non-usual pathogens, mainly Pseudomonas
aeruginosa, other gram-negative non-fermentative rods and Enterobacteriaceae, were iso-
lated among 71.1% of the sputum obtained during exacerbations; and, 3) these pathogens were
associated with poor prognosis and frequent hospitalization.71212165; fax: þ34 971212155.
ib.es (F. Renom).
9 Elsevier Ltd. All rights reserved.
Role of airway infection 841Conclusions: Airway infection by non-usual pathogens appears to be a key driver of frequent
hospitalizations and mortality in COPD.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Patients with chronic obstructive pulmonary disease (COPD)
often present with episodes of exacerbation (ECOPD) during
the course of their disease. These episodes are important
events in the natural history of COPD because they accel-
erate the decline of lung function, worsen the prognosis of
the patient1,2 and impose a significant economic burden on
society.3e5
Although the mechanisms of ECOPD are likely to be
multi-factorial, it is widely accepted that airway bacterial
infection plays a key pathogenic role.6 Besides, chronic
airway colonization is recognized today as an important
driver of COPD progression.7 Not all COPD patients,
however, have airway bacterial colonization, and the
frequency of ECOPD also varies greatly among them. Thus,
whereas some patients never present ECOPD, others exac-
erbate several times every year. Among the latter, there is
a subgroup of patients who are hospitalized repeatedly.8
The clinical, functional and microbiological characteristics
of these patients are poorly understood. We hypothesized
that airway infection by non-usual pathogens is a major
factor driving hospitalization requirements in these latter
subgroup of COPD patients.
In 2002, we instituted in our hospital an integrated,
multidisciplinary program aimed at providing clinical,
rehabilitation and educational support to patients with
advanced COPD (Online supplement Table E1), like others
have done before successfully.9e12 Therapeutic strategies
were established by severity levels in stable COPD, and
aiming to identify and manage ECOPD, according to GOLD
guidelines.13 Because one of the possible criteria for
inclusion in our program was that the patient had required
hospitalization because of ECOPD two or more times during
the last 12 months, this program offered us the opportunity
to characterize and follow-up this particular sub-population
of COPD patients. Accordingly, in this study we aimed: (1)
to describe their clinical and functional characteristics at
the time of inclusion in our program; (2) to determine
prospectively the microbiological pattern of airway infec-
tion during ECOPD; and, (3) to analyze the prognostic value
of several clinical, functional and microbiological variables
with respect to the frequency of hospitalizations and
mortality.
Methods
Patients
From October 2002 to December 2006, we included in our
program, after obtained informed consent, 202 patients
with advanced respiratory disease, of whom 140 required
two or more respiratory hospitalizations during the last 12
months. Of these, 116 were diagnosed of COPD according tothe GOLD guidelines.13 All patients with diagnoses other
than COPD were excluded of our study (Fig. 1).
Design of the study
This is an open cohort observational study. At the time of
inclusion in our program, clinical data were obtained in
stable phase (that is at least one month after the last
ECOPD). Spirometry was obtained in all subjects and in 107
of them, the 6 min walking distance (6MWD) was also
determined. Patients were then followed-up during an
average of 21 months (range, 1e51 months). During this
period, patients were visited every two months, or more
often if clinically required or by patient request. The study
protocol was approved by our Hospital Research
Committee.
Measurements
Dyspnea was quantified using the modified Medical
Research Council (mMRC) questionnaire.14 Co-morbidities
were assessed using the Charlson index.15 Spirometry was
measured according to standard international recommen-
dations.16 Reference values correspond to a Mediterranean
population.17 The 6-min walking distance (6MWD) was
determined following 2002 ATS guidelines.18 The BODE
index was calculated according to Celli et al.19
Culture of spontaneous sputum was obtained in all
ECOPD episodes that fulfilled GOLD criteria,13 occurred
during follow-up and, according to the criteria of
Anthonisen,20 were of potential infectious origin, whether
the patient was hospitalized or not. Culture of sputum was
not required in stable state.
The quality of sputum samples was assessed using the
scoring system of Murray and Washington.21 Sputum
samples were processed22 and bacterial colonies were
identified by standard methods23 in a central laboratory. All
isolates were tested for antibiotic susceptibility following
the CLSI (previously NCCLS) recommendations.24 Bacterial
isolates were grouped in two categories: usual pathogens,
including Haemophilus influenzae, Streptococcus pneumo-
niae, and Moraxella catarrhalis6,7,25e29; and non-usual
pathogens, including Pseudomonas aeruginosa and other
non-fermentative gram-negative rods (Stenotrophomonas
maltophilia and Achromobacter xylosoxidans), Enter-
obacteriaceae (Klebsiella pneumoniae, Escherichia coli,
Proteus mirabilis, Enterobacter cloacae, Serratia marces-
cens and Morganella morganii), Corynebacterium spp.
(Corynebacterium striatum in almost all isolates), methi-
cillin-resistant Staphyloccocus aureus (MRSA) and Asper-
gillus spp. Antibiotics used to treat each bacteria are listed
in the online supplement (Table E2).
For the analysis, patients were classified in four
different groups: 1) no pathogen (no pathogen isolates
Patients in the continuity of care for chronic advanced  
respiratory patients program(RESC), from October 2002 to December 2006 
202 patients 
Two or more hospitalizations One or no hospitalization 
in the previous year  in the pr evious year 
140 62 
COPD : 116 Other : 24: COPD : 46 Other : 16:    
Asthma: 8   Asthma: 6 
Bronchiectasis: 7 Bronchiectasis: 5 
Sequelae post  - TB: 4 Sequelae post  - TB: 0 
Ventilatory disorders: 5 Ventilatory disorders: 3 
Inters titial pulmonary disease: 3 Interstitial pulm. dis.: 1 
Not identified: 1 Not identified: 1 
Inclusion: Functional assessment in stable phase  
Control every two months (at the least) 
Sputum culture in all COPD exacerbations 
Outcome at 2 4 months : 
Lost: 18 (15,5%) Exitus: 35 (30,2%) Completers: 63 (54,3%) 
Outcome  at 51 months: 
Lost: 24 (20,7%) Exitus: 43 (37,1%) Completers: 49 (42,2%) 
Figure 1 Flow chart of selections of patients.
842 F. Renom et al.during follow-up); 2) usual pathogen (one or more usual
pathogens isolates); 3) non-usual pathogen (one or more
non-usual pathogens isolates) and 4) both (one or more
usual and non-usual pathogens isolates).
Statistical analysis
Results are presented as mean standard deviation, and
range or percentage as required. Continuous variables are
analyzed using the Student’s t-test and ANOVA, whereas
categorical variables are analyzed using the c2 test. Non-
parametric test (ManneWhitney U test, KruskaleWallis)
were used for variables that were not normally distributed.
A KaplaneMeier survival analysis was performed to analyze
mortality. The unadjusted association of predictors with
mortality was estimated with a bivariate semiparametric
Cox model. Due to in our cohort only a few patients were
classified in the first two quartiles of the BODE index (Q1
and Q2), both were pooled together for the survival analysis
and were used as the reference category. Those predictorsfound to be significantly associated with mortality in the
bivariate analysis were assessed in an extension of the
multivariate Cox’s proportional hazard model with time-
dependent co-variates.30,31 Hazard ratios and 95% confi-
dence intervals were calculated. Sputum culture was
introduced as a time-dependent co-variate, which allowed
to include the microbiological data collected at different
follow-up visits. Thus, any changes in the patient’s expo-
sures (i.e., changes in microbiological pattern) during
follow-up was taken into account. A p value lower than 0.05
was considered statistically significant. All statistical anal-
ysis were performed using SPSS v.15.0 and STATA v.8.0.
Results
Clinical and functional characteristics
Table 1 presents the main clinical and functional charac-
teristics of the 116 patients studied. Most of the patients
were male, mean age was 71 yrs and the mean of
Table 1 Clinical and functional characteristics of patients
(nZ 116, unless noted otherwise).
Mean SD Range
No of previous
hospitalizations/yr
3.2 1.4 2e8
Age, yrs 70.6 8.6 52e90
Males, % 109 (94%) e
Smoking history, pack-year 66.2 30.3 10e160
Current smokers, % 13 (11.2%) e
Charlson index 2.2 1 1e5
BMI, kg/m2 27.6 5.1 16.8e46.8
Dyspnea score, mMRC 2.7 0.8 1e4
FEV1/FVC, % 42.3 11.1 12e67
FEV1, % reference 36.5 13.4 13e77
GOLD I, n (%) 0 (0) e
GOLD II, n (%) 19 (16.4) e
GOLD III, n (%) 60 (51.7) e
GOLD IV, n (%) 37 (31.9) e
6MWD, meters (nZ 107) 262.6 114.3 30e500
BODE index (nZ 107) 5.5 2.1 1e9
BODE Q1, n (%) 8 (7.5%) e
BODE Q2, n (%) 25 (23.4%) e
BODE Q3, n (%) 39 (36,4%) e
BODE Q4, n (%) 35 (32,7%) e
BMI: body mass index; mMRC: modified medical research
council questionnaire; FEV1: forced expiratory volume in the 1st
second; 6MWD: 6 min walking distance; BODE index according to
Celli et al.19
Table 2 Number (and %) of patients with positive culture
results, and number (and %) of isolates identified during
follow-up.
Patientsf
NZ 80
Pathogen
isolates
NZ 377
Usual pathogen 51 109 (28.9%)
H. influenzae 30 (37.5%) 39 (10.3%)
S. pneumoniae 29 (36.3%) 42 (11.1%)
M. catarrhalis 24 (30%) 28 (7.4%)
Non-usual pathogen 68 268 (71.1%)
P. aeruginosa 46 (57.5%) 103 (27.3%)
Other non-fermentative
gram-negative rodsg
22 (27.5%) 49 (13%)
Enterobacteriaceaeh 21 (26.3%) 32 (8.5%)
Corynebacterium spp. 20 (25.0%) 34 (9%)
MRSAi 15 (18.8%) 41 (10.9%)
Aspergillus spp. 8 (10.0%) 9 (2.4%)
f Figures do not add up to total because patients may have
more than one pathogen isolated.
g Includes Stenotrophomonas maltophilia and Achromobacter
xylsoxidans.
h Includes Klebsiella pneumoniae, Escherichia coli, Proteus
mirabilis, Enterobacter cloacae, Serratia marcescens and Mor-
ganella morganii.
i Meticillin-resistant Staphylococcus aureus.
Role of airway infection 843hospitalizations because of ECOPD in the previous year was
3.2 1.4, (range 2e8 hospitalizations). The mean FEV1%
was 36.5 13.4 and the mean BODE index was 5.5 2.1 and
its quartile distribution revealed that 33 individuals (31%)
were only mildly impaired (Q1 or Q2).
Pattern of airway infection during ECOPD
Table 2 shows the number (and percentage) of patients
with positive sputum culture during the ECOPD episodes
that occurred during follow-up, as well as the number (and
percentage) of isolated pathogens during such episodes.
Eighty of the 116 patients (69%) presented at least one
positive sputum culture during follow-up, whereas this was
negative in 20 patients (17%) and could not be obtained in
16 patients (14%). Often, patients presented different
isolates in different cultures and/or more than one path-
ogen in the same culture (58 sputum cultures [18,2%] were
polymicrobial) (more information in the Online Supple-
ment, Figure E1). Overall, the total number of positive
sputum cultures was 318, in which 377 pathogens of 15
different species were isolated. Non-usual pathogens were
isolated about three times (71.1%) more often than usual
ones. P. aeruginosa was the non-usual pathogen most often
isolated (27.3%); it was identified in 46 of the 116 patients
studied (39.7%). When we analyze the association between
functional status and microbiological results, we observed
that FEV1% was not associated with microbiological group
(data not shown). We recorded in all participants the
previous use of home long-term oxygen therapy (LTOT) andnon-invasive mechanical ventilation: 48.7% of our patients
were using LTOT. Within this group non-usual germs were
isolated in 52.5% during follow-up, while in the non-LTOT
group they were similarly isolated in 55.2% (pZ 0.767).
Only 1.7% of included patients needed continuous positive
airways pressure (CPAP) and 3.4% bi-level positive airways
pressure (BiPAP). However using the multidimensional
BODE index we observed that the percentage of patients in
whom non-usual pathogens was recovered increased with
BODE severity (pZ 0.021) (Fig. 2). In fact, in patients with
the highest BODE index values (Q3 and Q4), non-usual
pathogens were isolated, alone or in combination with
other germs, in 96.2% and 91.7%, respectively, of the
positive sputum cultures obtained.
Hospitalizations and mortality
Because our patients were included in a specific health-
care program, the mean number of hospitalizations due to
ECOPD fell significantly from 3.2 in the year before entering
in the program to 1.4, and 1.3 at 12 and 24 months of
follow-up (p< 0.001) (Online supplement, Figure E2). Table
3 compares several clinical and functional baseline data
and microbiological results in patients with or without 2 or
more hospitalizations per year due to ECOPD during follow-
up. The distribution of bacterial isolates in sputum cultures
was significantly different in both groups (pZ 0.003). In
fact, sputum culture was sterile in 70.3% of those patients
requiring less than 2 hospitalizations during follow-up,
compared to 23.1% in the other group. Age was significantly
lower in those with two or more hospitalizations
(67.0 10.9 vs. 73.8 7.7 yrs; pZ 0.032). The remaining
37,50%
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Figure 2 Distribution of microbiology by patient BODE quartiles.
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not different between groups.
Sixty-four percent of patients were alive 24 months after
their inclusion in the program. Table 4 presents the asso-
ciation between clinical, functional and microbiological
variables and mortality at 24 months. The bivariate analysisTable 3 Comparison of several clinical, functional and
microbiological variables in patients with or without
frequent hospitalizations during follow-up.
<2 hosp/year
NZ 37
2 hosp/year
NZ 13
p
value
Age, yr. 73.8 7.7 67.0 10.9 0.032
BMI, kg/m2 28.1 3.5 25.9 5.5 0.157
Current smoker 1 (2.1%) 3 (23.1%) 0.052
Dyspnea, MMRC 2.5 0.7 2.8 0.7 0.168
Charlson index 2.2 1 2.5 1.2 0.439
FEV1, % ref 41.3 13.7 33.7 11.8 0.084
6 MWD, meters 278.6 109.8 255.2 104.6 0.618
BODE index 4.8 1.8 5.7 2.2 0.172
Sputum culture 0.003
No pathogen 26 (70.3%) 3 (23.1%)
Usual pathogen 4 (10.8%) 2 (15.4%)
Non-usual
pathogen
7 (18.9%) 5 (38.5%)
Both 0 (0) 3 (23.1%)
Results are shown as mean (SD), or percentage. Clinical and
functional data were determined at baseline. Microbiology
results correspond to those obtained during the first 6 months of
follow-up and the number of hospitalizations was recorded
during the next 12 months (only 50 patients had complete data
for all variables at 18 month of follow-up).showed that BMI, 6MWT, BODE quartiles and time-depen-
dent microbiological results were all significantly associ-
ated with mortality. In the multivariate analysis (Cox
regression), BODE quartiles and time-dependent microbio-
logical results remained independently associated with
mortality (see adjusted Hazard Ratio (HR) in Table 4). Fig. 3
presents the crude (panel A), and adjusted for baseline
BODE quartiles (panel B), survival curves according to
microbiological results determined during the first six-
months of follow-up. In both instances, the isolation of non-
usual pathogens, alone or in combination with other germs,
was associated with a statistically significant poorer
prognosis.
Discussion
This study investigates a particularly severe group of COPD
patients, those requiring frequent hospitalizations because
of COPD exacerbations, whose clinical, functional and
microbiological characteristics are poorly understood. Main
results show that: (1) not all of them had severe disease; (2)
sputum culture during ECOPD often identifies a wide range
of non-usual pathogens; and, (3) the latter are associated
with poorer prognosis.
Previous studies
Several previous studies have identified a number of factors
associated with the need of hospitalization in COPD. These
include advanced age, a history of three or more hospital-
izations in the previous year, the presence of poor quality
of life, severe dyspnea, depression and comorbidity, poor
lung function (low FEV1, low PaO2, high PaCO2), presence of
Table 4 Crude and adjusted associations of clinical, functional and microbiologic variables and 24-month mortality
Unadjusted HR (95% CI) Adjusted HR (95% CI)
Age, yr. 1.01
(0.98e1.05)
1.02
(0.98e1.06)
BMI, kg/m2 0.92
(0.86e0.99)
e
Current smoker 0.81
(0.25e2.64)
NS
Dyspnea, mMRC 1.57
(0.96e2.5)
e
Charlson index 0.98
(0.72e1.35)
NS
FEV1, % ref 0.99
(0.96e1.01)
e
6MWD (change of 35 m) 0.82
(0.68e0.93)
e
BODE quartiles (ref. category: quartile 1þ 2)
Quartile 3 1.16
(0.37e3.60)
0.78
(0.24e2.52)
Quartile 4 4.18
(1.55e11.27)
2.83
(1.01e7.94)
Sputum culture time dependent (ref. category: no pathogen)
Usual pathogen 0.40
(0.05e3.06)
0.62
(0.08e4.86)
Non-usual pathogen 3.88
(1.82e8.20)
3.36
(1.46e7.72)
Both 3.05
(1.15e8.06)
3.82
(1.27e11.48)
Role of airway infection 845pulmonary arterial hypertension and under prescription of
long-term oxygen therapy.32e35 Only a few authors,
however, have investigated specifically the population of
COPD patients studied here, that is those actually requiring
frequent hospitalizations (two or more per year). Decramer
et al.36 reported that this particular subgroup of patients
showed impaired ventilatory and peripheral muscle func-
tion, a physiological aspect that was not explored in our
study. In a retrospective study, Soler et al.8 reported that
patients hospitalized and/or attended at the emergency
room twice or more during the previous year were older and
had more severe lung function impairment. Finally, Cao
et al.37, conducted a cross-sectional survey of 186 patients
with moderate to severe COPD and a history of two or more
hospitalizations due to ECOPD during a one year period and
they found that the severity of airflow limitation, the
presence of psychosocial distress and the use of vaccination
were all associated with frequent hospitalizations. None of
these studies, however, analyzed the association of
microbiological results and hospitalization requirements.
Interpretation of findings
Our microbiological findings in this particular subgroup of
COPD patients are particularly relevant. On the one hand,
they are markedly at variance with previous studies in
ECOPD, where sputum culture is positive in about 50% of the
cases forH. influenzae (20e30%), S. pneumoniae (10e15%) or
M. catarrhalis (10e15%.)6,7,25e29,38e41 By contrast, a much
higher proportion of our patients (69%) showed a positivesputum culture during ECOPD at some point during follow-up
and, importantly, the proportion of non-usual pathogens
recovered (Table 2) was much higher (71%). This is particu-
larly evident for P. aeruginosa which is normally recovered in
5e10% of ECOPD,7 whereas it was isolated in 27.3% of our
patients. On the other hand, the high yield of isolations of
other non-fermentative gram-negative rods (S. maltophilia
and A. xylosoxidans often recovered in patients with bron-
chiectasis and cystic fibrosis,42,43 Enterobacteriaceae and S.
aureus (whose role in ECOPD is not well established),7 C.
striatum (recently identified as a potentially pathogen in
advanced COPD)44,45 and some fungus (such as Aspergillus
spp.) is also remarkable. Further, it is worth noting that one
third of P. aeruginosa and all the C. striatum isolated were
resistant to three or more antibiotic groups, that all the S.
aureus isolated were methicillin-resistant, that infections by
other non-fermentative gram-negative required specific
antibiotics, and that Aspergillus spp. infection required long-
term specific anti-fungal therapy. We found that sputum
cultures often yielded more than one pathogen (18.2%), that
the specific type of pathogen isolated often changed over
time in the same patient, and that the BODE index (Fig. 2)
were associated with the recovery of non-usual pathogens in
the sputum culture.
Finally, a unique characteristic of our study is that we
followed the patients prospectively for up to 51 months. By
doing so, several observations of interest arose. First, we
found that airway sterility was associated with a significant
reduction in the number of hospital admissions (Table 3),
supporting a role for airway infection as a risk factor for
Panel A. Unadjusted survival curves 
Panel B. Adjusted for BODE quart iles survival curves 
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Figure 3 KeM survival curves of patients with negative
results, usual, non-usual, and both pathogens obtained during
the first 6 months of follow-up.
846 F. Renom et al.frequent hospitalizations. Second, as reported previously,2
we found that mortality at two years was substantial (36%).
Interestingly, however, we also found that it was signifi-
cantly associated with the recovery of non-usual pathogens
in the sputum culture, particularly P. aeruginosa (Table 4
and Fig. 3). This observation is in keeping with previous
observations in patients with cystic fibrosis46 but contrasts
with a study by Murphy et al.47 in COPD patients. In any case,
it suggests that the therapeutic strategy in COPD patients
with frequent hospitalizations, such as those studied here,
has to consider, and eventually target, non-usual pathogens.
Potential limitations
Our study has some limitations that deserve comment. First,
we studied mostly males. This is quite often the case in
Spain, where females started to smoke much later. Our
results, therefore, cannot be extrapolated readily tofemales. Second, sputum cultures were obtained only during
those ECOPD episodes considered of likely infectious origin,
according to the criteria proposed by Anthonisen.20 Thus,
our study should be complemented by others investigating in
these patients the role of airway colonization during clinical
stability and other types of ECOPD episodes. Third, bron-
chiectasis were not specifically searched by high-resolution
computerized tomography, but recent studies that include
this tool,47,48 found bronchiectasis as a frequent complica-
tion in patients diagnosed of moderate and severe COPD.
Finally, this is not a pure observational study because our
patients were included in a integral and multidisciplinary
health-care program that reduce significantly the number of
hospitalizations due to ECOPD. Furthermore, our group is
focused in identification and treatment of pathogens
involved in airway infection. This may limit the generaliz-
ability of our results. Yet, we believe that the fact that we
have been able to identify several prognostic factors in
these patients despite the potential beneficial effect of the
program, actually strengthens the validity of our observa-
tions. We acknowledge that reporting additional information
such as arterial blood gases either at inclusion or at time of
exacerbations during follow-up, frequency of emergency
visits during the study period, and disease duration, could
have added relevant information about the characterization
and prognostic factors related to these patients, but
regrettably they were not collected systematically.
In a population of COPD patients who require frequent
hospitalizations airway infection by non-usual pathogens
(specially P. aeruginosa) appears to be a key driver of
mortality and hospitalization needs. Given the importance
of these two clinical outcomes, we propose that screening
and management of airway infection by non-usual patho-
gens should be considered in COPD patients who require
frequent hospitalizations.
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